Background Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are the most common pathogens causing genital tract infections. They cause a significant global morbidity and mortality and have been associated with increased risk of HIV transmission, mainly among key populations fueling STIs and HIV. Men who have sex with men (MSM) has been classified by the Moroccan National AIDS Program (NAP) as a vulnerable risk group with higher burden of STIs. The aim of the present study is to assess the prevalence of CT and NG among MSM in Marrakech.

Methods From October to December 2017, a total of 238 MSM were enrolled in the study using Respondent-Driven Sampling (RDS). Access to this population was facilitated by an NGO evolving in the field of HIV and STIs, with extensive experience with hard-to-reach population. Eligible recruits were aged of 18 years and older and having lived in Marrakech for the previous six months. Socio-demographic and behavioral factors were collected using a structured questionnaire. CT and NG investigations were performed using the Xpert CT/NG tests (Cepheid, USA) on anal swab samples.

Results The findings showed a prevalence of CT and NG of 9.24% (22/238) and 8.40 (20/238) respectively. A CT/NG co-infection was found in 3.36% (8/238) of cases. Fifty percent of MSM reported having passive anal sex with a male partner in the past six months and 44.1% have used Condom at the last passive anal sex.

Conclusion The prevalence of CT and NG among MSM in Marrakech has increased significantly compared to the results obtained in the first study conducted in 2010, which was 6.3% for CT and 2.4% for NG. These findings confirmed the need for the establishment and the expansion of programs targeting MSM in Morocco to strengthen the prevention and control the STIs among risky groups.

Disclosure No significant relationships.

Background HPV (sero) prevalence among young MSM visiting the STI clinic: opportunities for targeted HPV vaccination

HPV (SERO) PREVALENCE AMONG YOUNG MSM VISITING THE STI CLINIC: OPPORTUNITIES FOR TARGETED HPV VACCINATION

1Amina Hançali*, 2Bahija Bellaji, 3Nabea Jemmene, 1Nabila Sorea, 1Azzza Bennani, 1Latifa Ghargui, 1Houssine Rhilani, 1Kamal Alam, 1Mohamed Rhajouci. 1Institut National d’Hygiène, Ministry of Health Morocco, Rabat, Morocco; 2University Hospital Laboratory, Marrakech, Morocco; 3National STI/AIDS Program – Directorate of Epidemiology, Ministry of Health Morocco, Rabat, Morocco; 4UNAIDS – Morocco, Rabat, Morocco


Background Because men who have sex with men (MSM) are disproportionally affected by human papillomavirus (HPV) related cancers, countries might consider targeted HPV vaccination for MSM. We assessed the prevalence of vaccine-preventable HPV types among young MSM visiting sexually transmitted infection (STI) clinics in the Netherlands.

Methods We used data from MSM included in the PASSYON study, a biennial cross-sectional study among STI clinic visitors aged 16–24 years that started in 2009 when girls-only HPV vaccination was introduced. MSM were asked to provide a penile and anal swab for HPV DNA testing (including the vaccine-preventable types HPV6/11/16/18/31/33/45/52/58) and blood for HPV antibody testing (HPV16/18/31/33/45/52/58).

Results We included 575 MSM with a median age of 22 years and a median of 15 lifetime partners. No trends in penile or anal HPV prevalence over time were seen. Of the 455 MSM with both swabs available, 79%, 62% and 53% were HPV DNA negative at both anatomic sites for HPV16/18, HPV6/11/16/18 and HPV6/11/16/18/31/33/45/52/58 respectively. Most of these MSM who were HPV DNA negative, were also seronegative (80% for HPV16/18 and 70% for HPV16/18/31/33/45/52/58).

Conclusion The HPV prevalence among MSM did not decline since girls-only vaccination was introduced indicating that MSM are unlikely to benefit from herd effects from girls-only vaccination. Because the majority of young MSM visiting the STI clinic were (sero)negative for HPV16/18, the most important oncogenic types in males, targeting this group for HPV vaccination could still be beneficial.

Disclosure No significant relationships.
testing using Abbott CT/NG. When unpooling the samples, one discordant result was solved. Three CT infections (1 in each sampling site) and four NG infections (2A and 2P) were missed; one CT (P) and three NG (A) infection were found to be false positive (one in each sampling site). This converts into a respective sensitivity and specificity of 91.2% (95%CI: 76.3–98.1%) and 99.8% (95%CI: 99.0–100.0%) for CT and 88.6% (95%CI: 73.3–96.8%) and 99.4% (95%: 98.3–99.9%) for NG of the pooling strategy. Cohen’s Kappa agreement was 0.94 for CT and 0.89 for NG which is an almost perfect agreement.

Conclusion We showed that this pooling strategy performs well using the FDA approved point-of-care assay GeneXpert. This may be a very cost-effective strategy and also feasible, as the assay is widespread throughout the African continent for tuberculosis testing.

Disclosure No significant relationships.

P542 PREVALENCE OF STIS AMONG MSM INITIATING PREP IN WEST-AFRICA (COHMSM-PREP ANRS 12369 – EXPERTISE FRANCE)

1Irish De Baetselier*, 2Tania Crucitti, 3Ihsouf Yaya, 4Bintou Dembele, 5Epheen Mensah, 6Elies Dah, 7Arsamou Koné, 8Hortense Fayé-Ketté, 9Souda Diandé, 10Alain Yeo, 11Anoumou Dagnna, 12Christian Laurent, 13Bea Vuyioste, 14Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium; 15Institut Pasteur du Cameroun, Yaoundé, Cameroon; 16IRD, INSERM, Montpellier, France; 17ARCAD/SIDA, Bamako, Mali; 18Espoir Vie Togo, Lomé, Togo; 19Association African Solidarité, Ouagadougou, Burkina Faso; 20SEREO/UCRC, USTB, Bamako, Mali; 21Institut Côte d’Ivoire, Abidjan, Côte d’Ivoire; 22LNR-TB, Ouagadougou, Burkina Faso; 23CHU-SO-LNR-TB, Lomé, Togo; 24Institute of Tropical Medicine, Department of Public Health, Antwerp, Belgium

Background Men who have sex with men (MSM) coming forward for Pre-Exposure Prophylaxis (PrEP) are at high risk for HIV and other Sexually Transmitted Infections (STIs). However, little is known about the prevalence of STIs among MSM in West-Africa. Yet, understanding the STI epidemic among MSM will improve STI management. In the framework of a PrEP demonstration study in West-Africa (CohMSM-PrEP), we tested all participants for STIs at enrollment.

Methods The study was conducted in Abidjan-Côte d’Ivoire, Bamako-Mali, Lomé-Togo and Ouagadougou-Burkina Faso. Participants (n=507) were tested for the following STIs using the GeneXpert instrument: Chlamydia trachomatis (CT)/Neisseria gonorrhoeae (NG) in Anorectum (A), Urine (U) and Pharynx (P), and Trichomonas vaginalis (TV) in urine. Mycoplasma genitalium (MG) was tested using the S-DiagMGTV multiplex assay in A-U-P samples.

Results The overall prevalence of CT was 17.9% (19.4%, 22.0% 16.4%, and 13.6%) in Lomé, Abidjan, Bamako and Ouagadougou, respectively. Most CT infections were anorectal (12.3%), followed by urethral (5.7%). In Bamako, the second most infected sample type was pharyngeal (6.0%) instead of urine (5.0%). Overall prevalence of NG was 15.8% (9.7%; 25.0%; 6.0%; 22.3%) in Lomé, Abidjan, Bamako and Burkina, respectively. Most NG infections were found in the anorectum (10.7%), followed by the pharynx (5.7%). In Mali, no pharyngeal NG infections were detected. MG infection was 26.0% for Lomé and 27.6% for Ouagadougou (results for other sites not yet available). The majority of MG infections were found in the anorectum (15.4%). Among all participants, only one urine sample with TV has been found in Bamako.

Conclusion We showed a very high prevalence of extra-genital STIs among PrEP users in West-Africa. We also detected infections which would not have been treated if a syndromic management approach would have been applied (87.9%). In order to limit transmission of infections we recommend to test also extra-genital sites for STIs in this population.

Disclosure No significant relationships.

P543 COST-EFFECTIVENESS OF PRE-EXPOSURE PROPHYLAXIS IN MSM WITH EVENT-DRIVEN AND DAILY REGIMENS

1Maarten Reitsma*, 2Albert Jan Van Hoek, 3Maria Xiridou, 4Bingit Van Benthem, 5Arv Van Sighem, 6Maarten Schim Van Der Loef, 7Maria Prins, 8Elise Hoornenborg, 9Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven (RIVM), Bilthoven, Netherlands; 10National Institute for Public Health and the Environment (RIVM), Epidemiology and Surveillance, Centre for Infectious Diseases Control, Bilthoven, Netherlands; 11Stichting HIV Monitoring, Amsterdam, Netherlands; 12Public Health Service Amsterdam, Amsterdam University Medical Center (UMC), Infectious Diseases, Infection and Immunity (Alab II), Amsterdam, Netherlands; 13Public Health Service of Amsterdam, Amsterdam, Netherlands

Background Pre-exposure prophylaxis (PrEP) is highly effective in reducing HIV transmission among men who have sex with men (MSM). We investigated the impact of daily and event-driven PrEP on the transmission of HIV and N. gonorrhoeae (NG) and its cost-effectiveness in the Netherlands.

Methods We developed a stochastic agent-based transmission model of HIV and NG among MSM. We simulated three scenarios: (1) No PrEP; (2) Offering daily and event-driven PrEP; (3) Offering only daily PrEP. Three-monthly PrEP monitoring included testing for HIV, gonorrhoea, and other infections. From the Amsterdam PrEP Demonstration Project (AMPfEP) data, it was estimated that 27% of PrEP users prefer event-driven PrEP and they use half the amount of PrEP pills used by daily users. We assumed PrEP effectiveness was 86% regardless of regimen. Simulated outcomes of the transmission model were used in an economic model to calculate costs, quality-adjusted life-years (QALY), and incremental cost-effectiveness ratios (ICER), over 2018–2027, taking a health-care payer perspective. An ICER less than €20,000 per QALY gained was considered cost-effective.

Results PrEP resulted in 3,486 HIV infections averted and 1,482 QALYs gained over 2018–2027. Gonorrhoea prevalence dropped from 0.782% in 2017 to 0.023% in 2027. When offering both daily and event-driven PrEP, the costs for PrEP medication were €19 million over 2018–2027. This resulted in less total costs than when no PrEP is offered, making this programme cost-saving. With only daily PrEP, the costs for PrEP medication were €22 million over 2018–2027, making this programme cost-effective with a mean ICER of €217.40 per QALY gained.

Conclusion The PrEP programme (including STI monitoring) can be effective in reducing HIV incidence and gonorrhoea prevalence among MSM and can be cost-effective, even if all PrEP users prefer the daily regime. Monitoring of PrEP users can result in reductions in prevalence of STIs being monitored. Acknowledgements: AIDSfonds (2014037), ZonMw (522002003).

Disclosure No significant relationships.